Betnovate is a medication with the active ingredient betamethasone valerate. It is also known as Betamethasone or Betamethasone Valerate Cream. Betnovate is commonly used to treat skin conditions like eczema, psoriasis, and dermatitis by reducing redness, itching, and swelling.
You can expect to pay between £4.41 and £5.45 for Betnovate per creams. Prices vary with the packaging size and active ingredient quantity (5 or 10 gm).
Betnovate contains the active ingredient betamethasone valerate, a potent corticosteroid. Each gram of Betnovate cream or ointment typically contains 0.1% w/w of the active ingredient. Additional excipients and the specific formulation may vary slightly between the cream and ointment versions.
Betnovate is prescribed for the management and treatment of inflammatory skin conditions. These conditions include eczema, psoriasis, and dermatitis. It is also used in cases of lichen planus and discoid lupus erythematosus.
Betamethasone valerate works by reducing inflammation and suppressing the immune response. This is achieved through the inhibition of inflammatory mediators and suppression of neutrophil migration. Consequently, Betnovate reduces swelling, redness, and itching of the skin.
Betnovate should be applied thinly and evenly to the affected area. The standard frequency is once or twice daily, based on the severity of the condition. The duration of treatment should be limited to minimize potential side effects. Medical advice is required for dosage adjustment.
Clean and dry the affected area before application. Apply a small amount of Betnovate by gently massaging it into the skin. Avoid covering or bandaging the treated area unless instructed by a physician. Always wash hands after application unless they are the treated area. Do not apply Betnovate near the eyes, inside the mouth, or on mucous membranes.
Betnovate is contraindicated in patients with hypersensitivity to betamethasone valerate or any other component of the formulation. Additionally, it should not be used in viral skin infections such as herpes simplex, chickenpox, or vaccinia. It is also contraindicated in untreated bacterial and fungal infections of the skin.
Potential side effects include skin thinning, stretch marks, and localized burning or itching upon application. Long-term use may lead to more severe side effects like adrenal suppression and systemic absorption effects. Telangiectasia and perioral dermatitis are also possible with prolonged treatment.
Concomitant use of other corticosteroid-containing medications may enhance the effects and side effects of Betnovate. It may also interact with medications that alter corticosteroid metabolism. Always inform your healthcare provider of all medications you are taking, including over-the-counter drugs and supplements.
Store Betnovate at room temperature away from direct sunlight. Ensure the container is tightly closed when not in use. Keep out of reach of children. Do not freeze the medication, and discard it once expired or if the consistency changes.
Betnovate should be used with caution in pregnant and breastfeeding women. The safety and efficacy in children have not been established for long-term use. Elderly patients may be more susceptible to the effects due to thinner skin, thereby requiring a more cautious approach.
In the event of excessive application or signs of systemic absorption, immediate consultation with a healthcare provider is necessary. Symptomatic and supportive treatment is usually administered. Discontinuation or tapering of Betnovate might be required depending on the severity of the overdose.
Betamethasone valerate is absorbed through the skin, with the degree of absorption dependent on the integrity of the skin barrier. The medication undergoes metabolic degradation primarily in the liver. It is predominantly excreted through the renal pathway.
Periodic monitoring for HPA axis suppression is recommended in long-term or high-dose therapy. Observations for local skin reactions and signs of systemic absorption should be conducted. Regular follow-ups aid in adjusting the treatment plan as necessary.
Due to the greater ratio of skin surface area to body mass, children are more susceptible to systemic toxicity. Use with great caution, applying the minimal effective dosage under strict medical supervision. Avoid treatment durations exceeding the prescribed limit to mitigate risks.
Elderly patients often exhibit thinner skin, which increases the risk of local and systemic side effects. Reduced dose frequency or lower potency alternatives may be preferable. Close observation is advised to promptly identify and manage adverse reactions.
Betnovate should only be used during pregnancy if the potential benefits justify the potential risks to the fetus. Avoid extensive application in pregnant women. During breastfeeding, application should be limited to small areas, and the breast area should be avoided to prevent ingestion by the infant.
Inform patients about the correct application technique and the importance of adhering to prescribed dosages. Educate on recognizing and reporting adverse effects early. Emphasize the importance of follow-up appointments for ongoing evaluation.
Betnovate is available in various packaging, including tubes of cream and ointment. The sizes may vary from 15g to 100g depending on the market requirements. Always check the expiry date on the packaging before use.